ArticleCureus2025
Oral Amyloidosis Secondary to Tuberculosis in an Adult Patient: A Report of a Rare Case.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Oral amyloidosis involving the lateral border of the tongue secondary to tuberculosis is a rare clinical finding. We present the case of a 35-year-old woman with presumed amyloidosis secondary to tuberculosis after increased tongue volume and irregularly shaped lateral edges were noticed. The present study was motivated by the correlation between tuberculosis and its involvement as a trigger in the appearance of amyloidosis, which, in this case, presents with oral manifestations. This retrospective case report describes a patient whose incisional biopsy confirmed oral amyloidosis secondary to tuberculosis. The patient had a history of infectious diseases such as toxoplasmosis, histoplasmosis, cytomegalovirus, Epstein-Barr virus, and tuberculosis. The latter influenced the development of the amyloidosis process, suggesting an underlying immunological compromise that was not evaluated. The amyloidosis treatment begins with identifying the amyloid protein involved; since this is a serum amyloid A (SAA) protein, this finding is then related to the presence of an underlying chronic infectious inflammatory pathology.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.